Medicine and Dentistry
Neoplasm
84%
Esophageal Adenocarcinoma
72%
Overall Survival
66%
Meta-Analysis
46%
Circulating Tumor DNA
46%
Atezolizumab
46%
Cell-Free DNA
46%
Randomized Controlled Trial
36%
Oxaliplatin
32%
Progression Free Survival
31%
Arm
29%
Biological Marker
27%
Neoadjuvant Immunotherapy
27%
Fluoropyrimidine
26%
Neoadjuvant Therapy
26%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Overall Survival
75%
Esophageal Adenocarcinoma
69%
Adenocarcinoma
46%
Randomized Controlled Trial
39%
Immunotherapy
34%
Oxaliplatin
34%
Immune Checkpoint Inhibitor
30%
Fluoropyrimidine
29%
Recurrent Disease
26%
Survival Rate
26%
Progression Free Survival
26%
Microflora
25%
Cancer Recurrence
23%
Myoclonus
23%
Keyphrases
Gastroesophageal Cancer
50%
Curative Treatment
46%
Tumor Immune Microenvironment
46%
Neoadjuvant Chemoradiotherapy (nCRT)
32%
Cell-free DNA (cfDNA)
26%
Fecal Microbiota Transplantation
23%
Single-cell Proteomic Analysis
23%
DNA Characterization
23%
Overweight or Obesity
23%
Randomized Double-blind
23%
Placebo-controlled
23%
Esophageal Squamous Cell Carcinoma
23%
Human Epidermal Growth Factor Receptor 2 (HER2)
23%
Outcome Prediction
23%
Prognostic Factors
23%